Adalimumab – March 2026

• Brand names:
  • Yuflyma®
• Pharmaceutical Company:
  • CELLTRION HEALTHCARE AUSTRALIA PTY LTD
• Condition/Indication: Moderate to severe ulcerative colitis Severe juvenile idiopathic arthritis Severe chronic plaque psoriasis Severe Crohn disease Vision-threatening non-infectious uveitis
• Meeting Date: March 2026